Literature DB >> 27830958

Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis.

Omar Abdel-Rahman1.   

Abstract

BACKGROUND: This study assessed the prognostic impact of the liver-directed local tumor therapy in the management of hepatocellular carcinoma (HCC) with extrahepatic metastases.
METHODS: Metastatic HCC patients diagnosed between 2004 and 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. Propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TNM stage, site of metastases, fibrosis score and alpha fetoprotein).
RESULTS: A total of 2529 patients were identified. The median age was 65 years, and 151 patients received liver-directed local treatment (either surgical treatment or local destructive treatment). Both before and after propensity score matching, cancer-specific and overall survival (p < 0.0001 for all) were better in the liver-directed local therapy group. When the overall survival was stratified by the type of local treatment (surgical resection versus destructive treatment), both types of treatment improved overall survival (p < 0.0001 for both). In multivariate analysis of the matched population, the only factor correlated with better survival receiving is local therapy (p < 0.0001).
CONCLUSION: This analysis suggests that liver-directed local treatment may play a role -in addition to systemic treatment- in the management of selected patients with metastatic HCC. Further prospective randomized controlled trials are needed to confirm or deny this hypothesis.

Entities:  

Keywords:  HCC; Hepatocellular carcinoma; local treatment; surgery

Mesh:

Year:  2016        PMID: 27830958     DOI: 10.1080/17474124.2017.1259563

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  5 in total

1.  Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis.

Authors:  Hani Oweira; Ulf Petrausch; Daniel Helbling; Jan Schmidt; Meinrad Mannhart; Arianeb Mehrabi; Othmar Schöb; Anwar Giryes; Michael Decker; Omar Abdel-Rahman
Journal:  World J Gastroenterol       Date:  2017-03-14       Impact factor: 5.742

2.  A Surveillance, Epidemiology and End Results database analysis of the prognostic value of organ-specific metastases in patients with advanced prostatic adenocarcinoma.

Authors:  Yuyou Deng; Ran Bi; Zhenhua Zhu; Shengxian Li; Bo Xu; Wakeel Ahmad Rather; Chunxi Wang
Journal:  Oncol Lett       Date:  2019-06-07       Impact factor: 2.967

3.  Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis.

Authors:  Kangpyo Kim; Tae Hyung Kim; Tae Hyun Kim; Jinsil Seong
Journal:  J Hepatocell Carcinoma       Date:  2021-02-11

4.  Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.

Authors:  Omar Abdel-Rahman
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-17       Impact factor: 4.322

5.  The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.

Authors:  Ru Wang; Yayun Zhu; Xiaoxu Liu; Xiaoqin Liao; Jianjun He; Ligang Niu
Journal:  BMC Cancer       Date:  2019-11-12       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.